Human Genome Sciences (HGSI) is down 13.6% premarket after missing Q3...
Human Genome Sciences ( HGSI ) is down 13.6% premarket after missing Q3 estimates , and guiding for its year-end cash balance to be well below prior forecasts. Piper expects shares to "test recent...
View ArticleHuman Genome Sciences ([[HGSI]] +11%) pops on heavy volume. Earlier this week...
Human Genome Sciences ( HGSI +11% ) pops on heavy volume. Earlier this week the biotech group said it expected to post 2011 sales of $59M for its new lupus drug Benlysta. Although below analysts'...
View ArticleMore on Human Genome Sciences (HGSI): Q4 beats estimates across the board....
More on Human Genome Sciences ( HGSI ): Q4 beats estimates across the board. Revenue jumped 113% Y/Y on strong sales of Benlysta and lower R&D expenses. Shares +2.7% AH. Post your comment!
View ArticleGlaxoSmithKline ([[GSK]] -0.9%) appears to be going hostile in its $2.6B...
GlaxoSmithKline ( GSK -0.9% ) appears to be going hostile in its $2.6B unsolicited bid to buy U.S. biotech firm Human Genome Sciences ( HGSI -0.4% ). After HGSI rejected GSK 's offer two weeks ago, the...
View ArticleA Human Genome Sciences ([[HGSI]] -1.5%) shareholder sued the company's board...
A Human Genome Sciences ( HGSI -1.5% ) shareholder sued the company's board last week and asked a court to temporarily stop the firm from using its "poison pill" to prevent GSK's ( GSK ) hostile $2.6B...
View ArticleHuman Genome Sciences (HGSI): Q1 EPS of -$0.47 misses by $0.08. Revenue of...
Human Genome Sciences ( HGSI ): Q1 EPS of -$0.47 misses by $0.08 . Revenue of $47.1M (+77.1% Y/Y) beats by $1.1M . Shares -0.4% AH. ( PR ) Post your comment!
View ArticleShares of Human Genome Sciences ([[HGSI]] -7.1%) slide lower, extending a...
Shares of Human Genome Sciences ( HGSI -7.1% ) slide lower, extending a month-long losing streak that has seen HGSI's value diminish by over 20%. The negative sentiment has been driven in part by the...
View ArticleGlaxoSmithKline (GSK) agrees to acquire Human Genome Sciences (HGSI) for...
GlaxoSmithKline ( GSK ) agrees to acquire Human Genome Sciences ( HGSI ) for $3.6B, or $14.25 a share. HGSI shares +3% . ( PR) Post your comment!
View ArticleSources say GlaxoSmithKline (GSK) is poised to buy Human Genome Sciences...
Sources say GlaxoSmithKline ( GSK ) is poised to buy Human Genome Sciences ( HGSI ) for ~$2.8B, with an announcement likely during today's premarket session. The deal terms have reportedly been...
View ArticleHuman Genome Sciences (HGSI) said yesterday it's reviewing its strategic...
Human Genome Sciences ( HGSI ) said yesterday it's reviewing its strategic options , including a possible sale of the company. Human Genome rejected a $13/share bid from Glaxo last week and is likely...
View ArticleHuman Genome Sciences: Poison Pills Can Kill You If Your Suitor Walks Away
By Rocco Verducci : BMO recently downgraded Human Genome Sciences ( HGSI ) to Market Perform. This was based on the firm's belief that the risk of GlaxoSmithKline ( GSK ) rescinding its offer has...
View ArticleHuman Genome Sciences Lowers Albuferon Dosage
Human Genome Sciences HGSI announced Wednesday that all patients receiving 1200-microgram dosages of Albuferon in its Phase III trials will now receive dosages of 900 mcg, based on safety studies...
View ArticleCredit Rating Update: Human Genome Sciences
We're upgrading our credit rating for Human Genome Sciences HGSI to BB from B+ after taking into consideration the recent approval of the firm's lupus drug, Benlysta. The story surrounding Human Genome...
View ArticleWill Realism Prevail As GlaxoSmithKline Goes Hostile With $6.2 Billion Human...
By Proactive Investor : Shares in GlaxoSmithKline ( GSK ) fell in Wednesday morning trade in London after it went hostile with its bid to acquire the American biotech Human Genome Sciences ( HGSI )....
View ArticleHuman Genome Sciences: Analyzing The Road Ahead Now That It Is In Play
By Helix Investment Management : Headlines in the biotechnology sector are frequently dominated by M&A news, and as of April 19, there is a new M&A headline to discuss and analyze. Human Genome...
View ArticleBuy Human Genome Sciences, The Benefit May Outweigh The Risk
By Rx Stocks : An offer on the table from GlaxoSmithKline ( GSK ), $13 per share for Human Genome Sciences, Inc. ( HGSI ), normally would have put a floor under the share price. But Human Genome...
View ArticleHuman Genome Sciences - Investors Are Speculating On A Higher Bid
By Robert Broens : Shares of Human Genome Sciences ( HGSI ) almost doubled today after GlaxoSmithKline made a $13 offer for the company. Shares ended the day 98% higher to close at $14.17 The Deal...
View Article4 Biotech Stocks Beyond Human Genome Sciences To Consider Now
By Vatalyst : Buyout and takeover news usually rocks the market, and the potential changes concerning Human Genome Sciences ( HGSI ) and GlaxoSmithKline ( GSK ) are no exception. Human Genome Sciences...
View ArticleHuman Genome Sciences HGSI Q4 2011 Earnings Call Transcript
Good day everyone and welcome to the Human Genome Sciences' Fourth Quarter 2011 and Full Year Financial Results Webcast. Today's webcast is being recorded. At this time, I will turn things over to Mr....
View ArticleIs There Time Left To Buy Human Genome Sciences?
By Rx Stocks : Last weekend, Reuters reported that Celgene ( CELG ) was mulling a bid for Human Genome Science, Inc. ( HGSI ). This weekend, Reuters reports that GlaxoSmithKline ( GSK ) is engaging in...
View Article
More Pages to Explore .....